-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Compileriver
When Johnson & Johnson launched the first products of its new crown vaccine in the United States, it was already focusing on the next pandemic.
A few days ago, Johnson & Johnson subsidiary Janssen will invest US$27 million to purchase Cidara’s leading antiviral conjugate CD388, which can treat and prevent all influenza strains with a single dose.
The current flu vaccine has several major limitations.
Cidara is responsible for R&D and production to the second phase.
Jeffrey Stein said in a conference call with investors on Monday morning that there is still a $753 million R&D budget and milestones waiting for Cidara, as well as "medium to high digit" tiered royalties.
The Janssen agreement also includes Cidara's another AVC candidate project CD377, which has a slightly shorter duration.
In addition to the agreement between Cidara and Mundipharma on its main antifungal project Rezafungin in 2019, the biotech company will receive up to US$1.
Reference source: With one pandemic still raging, J&J bets $780M on a potential flu therapy for the next